Trials / Completed
CompletedNCT00291356
GSK189075, GW869682 Or Placebo In Type 2 Diabetic Patients
A Double-blind, Randomized, Placebo-controlled, Repeat Dose Study to Compare the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK189075 With GW869682 in Subjects With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 45 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 30 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a study to compare the safety, blood concentrations, and effects of GSK189075, GW869682, and placebo when dosed for 2-weeks by mouth to patients with type 2 diabetes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GSK189075 oral tablets | |
| DRUG | GW869682 oral tablets |
Timeline
- Start date
- 2006-01-01
- Primary completion
- 2006-05-01
- Completion
- 2006-05-01
- First posted
- 2006-02-14
- Last updated
- 2015-04-15
Locations
3 sites across 2 countries: United States, Germany
Source: ClinicalTrials.gov record NCT00291356. Inclusion in this directory is not an endorsement.